Compare DIBS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIBS | AGEN |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.7M | 178.2M |
| IPO Year | 2021 | 1999 |
| Metric | DIBS | AGEN |
|---|---|---|
| Price | $5.53 | $3.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $14.50 |
| AVG Volume (30 Days) | 133.9K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.45 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,620,000.00 | $42,877,086.00 |
| Revenue This Year | $3.12 | $107.63 |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | 1.54 | ★ 89.95 |
| 52 Week Low | $2.35 | $2.63 |
| 52 Week High | $6.62 | $7.34 |
| Indicator | DIBS | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 49.63 |
| Support Level | $5.27 | $3.92 |
| Resistance Level | $5.63 | $4.58 |
| Average True Range (ATR) | 0.23 | 0.40 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 13.58 | 22.67 |
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.